eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2016
vol. 33
 
Share:
Share:
abstract:
Review paper

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

Agnieszka Wasilewska
,
Marta Winiarska
,
Małgorzata Olszewska
,
Lidia Rudnicka

Adv Dermatol Allergol 2016; XXXIII (4): 247–252
Online publish date: 2016/08/16
View full text Get citation
 
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment – a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
keywords:

alopecia areata, fynomer, lichen planus, pemphigoid, pemphigus

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.